Stock 605016 SHANDONG BAILONG CHUANGYUAN BIO-TECH CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Shandong Bailong Chuangyuan Bio-Tech Co., Ltd.

Equities

605016

CNE1000052N4

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-06-04 pm EDT 		5-day change 1st Jan Change
22.95 CNY -1.49% Intraday chart for Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. -1.16% +5.07%
May. 29 Bailong Chuangyuan Bio-Tech Completes Dietary Fiber Plant Construction MT
Apr. 26 Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Summary

  • From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

  • Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
  • The company's profit outlook over the next few years is a strong asset.
  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.

Weaknesses

  • With a 2024 P/E ratio at 26.75 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
  • The company appears highly valued given the size of its balance sheet.
  • The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
  • The overall consensus opinion of analysts has deteriorated sharply over the past four months.
  • Over the past twelve months, analysts' opinions have been revised negatively.
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Food Processing

1st Jan change Capi. Investor Rating ESG Refinitiv
SHANDONG BAILONG CHUANGYUAN BIO-TECH CO., LTD. Stock Shandong Bailong Chuangyuan Bio-Tech Co., Ltd.
+5.07% 1.02B -
SÜDZUCKER AG Stock Südzucker AG
+0.42% 3.14B
B+
COSUMAR SA Stock Cosumar SA
-1.03% 1.84B
B-
SÃO MARTINHO S.A. Stock São Martinho S.A.
-8.15% 1.76B
C+
SHREE RENUKA SUGARS LIMITED Stock Shree Renuka Sugars Limited
-13.57% 1.01B -
C-
ADECOAGRO S.A. Stock Adecoagro S.A.
-15.95% 970M
B
BALRAMPUR CHINI MILLS LIMITED Stock Balrampur Chini Mills Limited
-5.87% 946M
B
TRIVENI ENGINEERING & INDUSTRIES LIMITED Stock Triveni Engineering & Industries Limited
-8.34% 860M
B-
SHANDONG SANYUAN BIOTECHNOLOGY CO.,LTD. Stock Shandong Sanyuan Biotechnology Co.,Ltd.
-7.72% 744M -
HONGMIAN ZHIHUI SCIENCE AND TECHNOLOGY INNOVATION CO.,LTD.GUANGZHOU Stock Hongmian Zhihui Science and Technology Innovation Co.,Ltd.Guangzhou
-6.05% 747M - -
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
-
Earnings quality
  1. Stock Market
  2. Equities
  3. 605016 Stock
  4. Ratings Shandong Bailong Chuangyuan Bio-Tech Co., Ltd.